1. Home
  2. MESO vs TCBK Comparison

MESO vs TCBK Comparison

Compare MESO & TCBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • TCBK
  • Stock Information
  • Founded
  • MESO 2004
  • TCBK 1975
  • Country
  • MESO Australia
  • TCBK United States
  • Employees
  • MESO 81
  • TCBK N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • TCBK Major Banks
  • Sector
  • MESO Health Care
  • TCBK Finance
  • Exchange
  • MESO Nasdaq
  • TCBK Nasdaq
  • Market Cap
  • MESO 2.0B
  • TCBK 1.4B
  • IPO Year
  • MESO N/A
  • TCBK N/A
  • Fundamental
  • Price
  • MESO $15.60
  • TCBK $44.42
  • Analyst Decision
  • MESO Buy
  • TCBK Buy
  • Analyst Count
  • MESO 2
  • TCBK 5
  • Target Price
  • MESO $24.00
  • TCBK $48.60
  • AVG Volume (30 Days)
  • MESO 213.4K
  • TCBK 102.8K
  • Earning Date
  • MESO 08-28-2025
  • TCBK 10-23-2025
  • Dividend Yield
  • MESO N/A
  • TCBK 3.24%
  • EPS Growth
  • MESO N/A
  • TCBK 5.66
  • EPS
  • MESO N/A
  • TCBK 3.55
  • Revenue
  • MESO $17,198,000.00
  • TCBK $399,268,000.00
  • Revenue This Year
  • MESO $288.50
  • TCBK $9.49
  • Revenue Next Year
  • MESO $167.17
  • TCBK $5.50
  • P/E Ratio
  • MESO N/A
  • TCBK $12.51
  • Revenue Growth
  • MESO 191.39
  • TCBK 3.12
  • 52 Week Low
  • MESO $8.34
  • TCBK $35.20
  • 52 Week High
  • MESO $22.00
  • TCBK $51.06
  • Technical
  • Relative Strength Index (RSI)
  • MESO 39.64
  • TCBK 55.59
  • Support Level
  • MESO $16.10
  • TCBK $43.22
  • Resistance Level
  • MESO $16.91
  • TCBK $44.98
  • Average True Range (ATR)
  • MESO 0.50
  • TCBK 1.10
  • MACD
  • MESO -0.27
  • TCBK 0.26
  • Stochastic Oscillator
  • MESO 0.60
  • TCBK 87.67

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

About TCBK TriCo Bancshares

TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.

Share on Social Networks: